Clinical trial
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant…
NCT00068367 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00068367 |
|---|---|
| Title | S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor |
| Official title | U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 24 |
| Start date | Dec 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Aug 1, 2009 |
| First posted | Sep 11, 2003 |
| Last update posted | Nov 6, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: